New hope for advanced breast cancer patients as experimental drug enters final testing phase
NCT ID NCT07071337
Summary
This study is testing whether a new drug called SKB264 works better than standard chemotherapy for people with advanced breast cancer that has stopped responding to hormone therapy. It will involve about 430 participants with HR+/HER2- breast cancer that has spread or returned. The main goal is to see if SKB264 can slow cancer growth longer than current chemotherapy options while monitoring side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Fifth Medical Center of the Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100039, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.